Antibodies
OwnerSriram Sathyanarayanan, Shailaja Kashibhatla +2inventors
InventorsSriram Sathyanarayanan, Shailaja Kashibhatla, Christopher Winter, Michael Chastain
Life of this patent
Estimating the term…
Abstract
The combination of an IGF-1R antagonist such as a humanized antibody and an anti-proliferative drug is described. In a preferred embodiment, the present invention describes the combination of an IGF-1R antibody and an anti-proliferative drug belonging to the EGFR-inhibitor class, which is preferably erlotinib. The combination according to the present invention is useful for the treatment of tumours, including IGF-1R and/or EGFR mediated or dependent tumours.
Claims22
A method of treating or preventing a medical condition in a subject comprising:
- administering a therapeutically effective amount of combination therapeutic comprising a tyrosine kinase inhibitor and an IGF-1R inhibitor or a pharmaceutical composition thereof to said subject, wherein administration of the combination therapeutic results in enhanced therapeutic efficacy relative to administration of the EGFR inhibitor or IGF-1R inhibitor alone, sufficient to treat said patient.
The method according to 11, wherein the tyrosine kinase inhibitor is Erlotinib and is administered five times a week.
Dependencies are inferred from the claim text.